Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer.
about
Hepatocyte growth factor/MET in cancer progression and biomarker discoveryIdentification of serum proteins and multivariate models for diagnosis and therapeutic monitoring of lung cancer.Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancerDepth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy.The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition.Biomarkers of gastric cancer: Current topics and future perspective
P2860
Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Serum level of hepatocyte grow ...... ith metastatic gastric cancer.
@en
type
label
Serum level of hepatocyte grow ...... ith metastatic gastric cancer.
@en
prefLabel
Serum level of hepatocyte grow ...... ith metastatic gastric cancer.
@en
P2093
P2860
P356
P1433
P1476
Serum level of hepatocyte grow ...... ith metastatic gastric cancer.
@en
P2093
Atsuo Takashima
Hirokazu Shoji
Hirokazu Taniguchi
Koh Furuta
Naoki Takahashi
Natsuko Okita
Satoru Iwasa
Tetsuya Hamaguchi
Yasuhide Yamada
P2860
P304
P356
10.18632/ONCOTARGET.6753
P407
P577
2015-12-24T00:00:00Z